Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Blueprint Medicines Corp (BPMC)

96.91   -5.99 (-5.82%) 01-27 03:32
Open: 103.62 Pre. Close: 102.9
High: 104 Low: 96.54
Volume: 300,105 Market Cap: 5,401M
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 104.122 - 104.67 104.67 - 105.137
Low: 95.304 - 95.895 95.895 - 96.398
Close: 95.944 - 96.942 96.942 - 97.792

Technical analysis

as of: 2021-01-26 4:41:45 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 133.74     One year: 146.71
Support: Support1: 96.54    Support2: 80.32
Resistance: Resistance1: 114.51    Resistance2: 125.61
Pivot: 103.43
Moving Average: MA(5): 101.05     MA(20): 106.11
MA(100): 99.84     MA(250): 80.55
MACD: MACD(12,26): -2.95     Signal(9): -2.03
Stochastic oscillator: %K(14,3): 16.71     %D(3): 16.36
RSI: RSI(14): 35.51
52-week: High: 125.61  Low: 43.29  Change(%): 46.6
Average Vol(K): 3-Month: 50197  10-Days: 35130

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
BPMC has closed below the lower band by 4.5%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 31.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 26 Jan 2021
Blueprint Medicines Corporation (BPMC) Plunges 5.82% on January 26 - Equities.com

Tue, 12 Jan 2021
SVB Leerink Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $127.00 - MarketBeat

Thu, 07 Jan 2021
Blueprint Medicines Reaches Analyst Target Price - Nasdaq

Mon, 04 Jan 2021
Should You Buy Blueprint Medicines Corp (BPMC) Stock Monday? - InvestorsObserver

Mon, 21 Dec 2020
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why - Yahoo Finance

Wed, 16 Dec 2020
Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $595,900 of Shares - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 56
Shares Float (M) 55
% Held by Insiders 0.79
% Held by Institutions 104.33
Shares Short (K) 3,100
Shares Short P. Month (K) 3,450

Stock Financials

EPS 6.180
EPS Est This Year -3.660
EPS Est Next Year -4.410
Book Value (p.s.) 24.210
Profit Margin 41.08
Operating Margin 40.10
Return on Assets (ttm) 17.7
Return on Equity (ttm) 36.3
Qtrly Rev. Growth 8053.2
Gross Profit (p.s.) -4.754
Sales Per Share 14.555
EBITDA (p.s.) 5.953
Qtrly Earnings Growth
Operating Cash Flow (M) 367
Levered Free Cash Flow (M) 226

Stock Valuations

PE Ratio 15.68
PEG Ratio
Price to Book value 4.00
Price to Sales 6.66
Price to Cash Flow 14.72

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.